In August 2026, Bausch + Lomb announced new real-world data on its enVista Aspire™ (EA) and enVista Aspire™ Toric (ETA) enhanced monofocal intraocular lenses.

The multicenter retrospective study was published in Ophthalmology and Therapy and included 84 patients and 141 eyes, comprising 88 eyes implanted with enVista Aspire and 53 eyes implanted with enVista Aspire Toric.

The study evaluated how the two enhanced monofocal IOLs performed in routine clinical practice, with a particular focus on distance vision, intermediate vision, refractive outcomes, safety and surgeon experience.

Optical Design: A 1.5 mm Central Zone Extends Depth of Focus

enVista Aspire is based on Bausch + Lomb’s enVista hydrophobic acrylic IOL platform.

The lens incorporates an optical modification on the posterior aspheric surface, creating a small continuous increase in IOL power within the central 1.5 mm diameter.

The design is intended to broaden depth of focus from distance toward intermediate vision while maintaining a visual profile similar to that of a conventional monofocal lens.

The toric version, enVista Aspire Toric, is designed for patients who also require correction of corneal astigmatism.

A previously published prospective study reported approximately 1.50 D of continuous depth of focus at 0.2 logMAR or better with the enVista Aspire platform.

Core Data: Distance Vision Remained Strong, Intermediate Vision Reached 93%

This real-world study used visual outcomes from the last available postoperative visit, with follow-up ranging from approximately Day 1–6 to four months.

Study design and key data

The study was a multicenter retrospective real-world case series involving six cataract surgeons in the United States.

A total of 141 eyes from 84 patients were included:

• enVista Aspire: 88 eyes

• enVista Aspire Toric: 53 eyes

Patients ranged in age from 62 to 84 years.

Distance visual acuity

At the last available postoperative visit, 97.2% of enVista Aspire eyes and 94.9% of enVista Aspire Toric eyes achieved monocular corrected distance visual acuity (CDVA) of 20/25 or better.

For monocular uncorrected distance visual acuity (UDVA) of 20/25 or better, the rates were:

• 71.3% for enVista Aspire

• 84.9% for enVista Aspire Toric

Intermediate visual acuity

For monocular uncorrected intermediate visual acuity (UIVA) of 20/32 or better, the rates were:

• 76.6% for enVista Aspire

• 93.0% for enVista Aspire Toric

For patients with available binocular intermediate-vision data, 100% achieved binocular UIVA of 20/32 or better in both groups.

Refractive outcomes

Mean spherical equivalent outcomes were close to the intended refractive target:

• enVista Aspire: −0.06 ± 0.30 D

• enVista Aspire Toric: 0.00 ± 0.32 D

These data indicate that refractive outcomes remained close to plano in both groups.

Safety

No serious adverse events were documented in the available clinical records.

The study also reported no documented glistenings in either group, although glistenings were not a prespecified item in the case report form and would therefore only have been captured if spontaneously recorded.

Surgeon Satisfaction: Overall Scores Reached 10/10

The study also included a retrospective surgeon-experience survey.

Six cataract surgeons participated. The median annual cataract surgery volume was 1,900 cases, with a range of 450 to 4,500 cases per year.

The surgeons reported using a mix of full-range-of-vision IOLs, enhanced monofocal IOLs and toric IOLs in routine practice.

According to the study, surgeon feedback on enVista Aspire and enVista Aspire Toric was positive across several parameters, including centration, visual disturbances and visual outcomes.

In the survey data reported by Bausch + Lomb, 83% of surgeons rated overall satisfaction with enVista Aspire at 9 or higher out of 10, while 100% gave enVista Aspire Toric a score of 9 or higher.

Clinical Significance and Study Positioning

Enhanced monofocal IOLs are designed to provide stronger intermediate vision than conventional monofocal lenses while avoiding some of the optical trade-offs associated with multifocal or extended-depth-of-focus IOLs.

For patients undergoing cataract surgery, intermediate vision has become increasingly relevant for activities such as computer use, smartphone viewing and other daily tasks.

The current study provides real-world evidence showing that enVista Aspire and enVista Aspire Toric can maintain strong distance visual acuity while providing functional intermediate vision in routine clinical practice.

However, the study was retrospective, used a convenience sample and did not include a randomized control group.

The authors also noted that larger prospective comparative studies are still needed to confirm these findings.

Real-World Evidence Adds to the Existing Clinical Data

The study adds real-world data to the existing clinical evidence for enVista Aspire.

Compared with controlled clinical studies, retrospective real-world studies can provide information on how a product performs across different surgeons and routine clinical settings.

In this study, the visual, refractive and safety outcomes reported across six surgeons were broadly consistent with previously published prospective findings.

The authors concluded that enVista Aspire and enVista Aspire Toric were associated with favorable distance and functional intermediate vision, refractive accuracy close to target and no serious adverse events documented in the available clinical records.

For Bausch + Lomb, the publication provides additional evidence supporting the clinical use of its enhanced monofocal IOL platform.

Further prospective comparative studies and longer follow-up will be important for evaluating the durability of these outcomes and the performance of the lenses across broader patient populations.

September 9, 2026